Combined use of FoxM1 inhibitor, thiostrepton and the PI3K/mTOR dual inhibitor, GSK458, synergistically promotes an anticancer effect in ovarian clear cell carcinoma

Activating mutations in PIK3CA encoding p110a, the catalytic subunit of PI3K, have been described to occur in 33%–40% of OCCC. To testify whether Thiostrepton and GSK458 could exert synergistic anti-tumor effects against OCCC, we use RNA sequence from TOV21G cell line therapy groups. Overall design: The groups were divided into four groups-Control group, thiostrepton (1uM) monotherapy, GSK458 (0.1uM) monotherapy, thiostrepton combined with GSK458 group for 48h. Total RNA was extracted using the Qiagen RNeasy Mini Kit (Qiagen, Venlo, Netherlands). RNA integrity was evaluated using the Agilent 2100 Bioanalyzer RNA Nano Chip (Agilent Technologies, Santa Clara, CA, USA). There is one sample for each group. Totally there are four samples from each therapy group.